A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB

被引：0

作者：

Ajani, J. A. ^{[1
]}

Udrea, A. ^{[2
]}

Sarosiek, T. ^{[3
]}

Shenker, M. ^{[4
]}

Morgan, C. ^{[5
]}

Pikiel, J. ^{[6
]}

Wojcik, E. ^{[7
]}

Swinson, D. ^{[8
]}

Joseph, M. ^{[9
]}

Luft, A. ^{[10
]}

Salek, T. ^{[11
]}

Tournigand, C. ^{[12
]}

Ferry, D. ^{[13
]}

Zhang, Y. ^{[13
]}

Long, A. ^{[13
]}

Kuo, W-L. ^{[13
]}

Gao, L. ^{[13
]}

Kauh, J. ^{[13
]}

Mansoor, W. ^{[14
]}

机构：

[1] Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA

[2] MedisProf SRL, Oncol, Cluj Napoca, Romania

[3] Magodent, Oncol, Warsaw, Poland

[4] Sf Nectarie SRL, Ctr Oncol, Craiova, Romania

[5] Velindre Canc Ctr, Oncol, Cardiff, S Glam, Wales

[6] COPERNICUS Podmiot Leczniczy, Oncol, Gdansk, Poland

[7] NZOZ Ctr Med HCP, Oncol, Poznan, Poland

[8] St James Univ Hosp, St Jamess Inst Oncol, Leeds, W Yorkshire, England

[9] New Cross Hosp, Deanesly Ctr, Wolverhampton, England

[10] Leningrad Reg Clin Hosp, Oncol, St Petersburg, Russia

[11] Narodny Onkol Ustav, Oncol, Bratislava, Slovakia

[12] CHU Henri Mondor, Oncol, Creteil, France

[13] Eli Lilly & Co, Oncol, Bridgewater, NJ USA

[14] NHS Fdn Trust, Christie Hosp, Manchester, Lancs, England

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

698P

引用

页数：1

共 50 条

[1] Ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Secondary analysis of efficacy and safety results of 4 dosing regimens in the phase II trial I4T-MC-JVDB
Ajani, Jaffer A.
Udrea, Anghel Adrian
Sarosiek, Tomasz
Schenker, Michael
Morgan, Carys
Pikiel, Joanna
Joseph, Mano
Salek, Tomas
Tournigand, Christophe
Ferry, David Raymond
Zhang, Yawei
Long, Amanda
Kuo, Wen-Ling
Gao, Ling
Russo, Francesca
Mansoor, Wasat
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[2] Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF)
Chau, Ian
Penel, Nicolas
Arkenau, Hendrik-Tobias
Santana-Davila, Rafael
Calvo, Emiliano
Soriano, Andres O.
Mi, Gu
Jin, Jin
Ferry, David
Herbst, Roy S.
Fuchs, Charles S.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[3] Multicenter phase I dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma
Li, Sheng
Bao, Jun
Li, Xiaoyou
Yang, Quanliang
Xu, Junying
Chen, Surong
Feng, Ge
Gao, Chao
Feng, Lin
Lu, Bin
Miao, Min
Ni, Xinchu
Wang, Guofang
Yang, Lei
Zhu, Liangjun
ECLINICALMEDICINE, 2023, 66
[4] A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results
Herbst, Roy S.
Bendell, Johanna C.
Isambert, Nicolas
Calvo, Emiliano
Santana-Davila, Rafael
Cassier, Philippe
Perez-Gracia, Jose Luis
Yang, Jing
Rege, Jessicca
Ferry, David
Mi, Gu
Chau, Ian
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study
Kensei Yamaguchi
Kazumasa Fujitani
Fumio Nagashima
Yasushi Omuro
Nozomu Machida
Tomohiro Nishina
Toshiko Koue
Mika Tsujimoto
Kaijiro Maeda
Taroh Satoh
Gastric Cancer, 2018, 21 : 1041 - 1049
[6] Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study
Yamaguchi, Kensei
Fujitani, Kazumasa
Nagashima, Fumio
Omuro, Yasushi
Machida, Nozomu
Nishina, Tomohiro
Koue, Toshiko
Tsujimoto, Mika
Maeda, Kaijiro
Satoh, Taroh
GASTRIC CANCER, 2018, 21 (06) : 1041 - 1049
[7] Dose-escalation and Dose-expansion Study of Trastuzumab-deruxtecan(T-Dxd) Monotherapy and Combinations in Patients with advanced/metastatic HER2+Gastric Cancer (GC)/Adenocarcinoma of the gastroesophageal Junction (GEJA): DESTINY-Gastric03
Lordick, F.
Janjigian, Y. Y.
Oh, D. -Y.
Rha, S. Y.
Lee, K. -W.
Steeghs, N.
Chao, Y.
Di Bartolomeo, M.
Diez, Garcia M.
Haj, Mohammad N.
Stein, A.
McAdoo, W.
Winter, M.
Croydon, E.
Lee, J.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 222 - 222
[8] Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03
Stein, Alexander
Lordick, Florian
Janjigian, Yelena Y.
Oh, Do-Youn
Lee, Keun-Wook
Steeghs, Neeltje
Chao, Yee
Di Bartolomeo, Maria
Garcia, Marc Diez
Mohammad, Nadia Haj
Mcadoo, William
Winter, Megan
Croydon, Elizabeth
Lee, Jeeyun
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 94 - 94
[9] Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03
Janjigian, Yelena Y.
Oh, Do-Youn
Rha, Sun Young
Lee, Keun Wook
Steeghs, Neeltje
Chao, Yee
Di Bartolomeo, Maria
Garcia, Marc Diez
Mohammad, Nadia Haj
Stein, Alexander
McAdoo, William
Winter, Megan
Croydon, Liz
Lee, Jeeyun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[10] PD-L1 mRNA expression in patients with resectable gastric cancer and adenocarcinoma of the oesophago-gastric junction undergoing perioperative chemotherapy: Results from the FLOT4 phase III trial of the AIO.
Waberer, Lisa
Homann, Nils
Wirtz, Ralph M.
Schmalenberg, Harald
Haag, Georg Martin
Schuler, Martin H.
Kasper, Stefan
Goetze, Thorsten Oliver
Pauligk, Claudia
Hofheinz, Ralf
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →